Cited by 146Multiple Sclerosis Research StudiesNeuroinflammation and Neurodegeneration MechanismsPeripheral Neuropathies and Disorders

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: A retrospective study

Open access
Trapp, Bruce D, Vignos, Megan, Dudman, Jessica, Chang, Ansi, Fisher, Elizabeth, Staugaitis, Susan M, Battapady, Harsha, Mork, Sverre +6 more·2018·The Lancet Neurology

Abstract

Background Demyelination of cerebral white matter is thought to drive neuronal degeneration and permanent neurological disability in individuals with multiple sclerosis. Findings from brain MRI studies, however, support the possibility that demyelination and neuronal degeneration can occur independently. We aimed to establish whether post-mortem brains from patients with multiple sclerosis show pathological evidence of cortical neuronal loss that is independent of cerebral white-matter demyelination. Methods Brains and spinal cords were removed at autopsy from patients, who had died with multiple sclerosis, at the Cleveland Clinic in Cleveland, OH, USA. Visual examination of centimetre-thick slices of cerebral hemispheres was done to identify brains without areas of cerebral white-matter discoloration that were indicative of demyelinated lesions (referred to as myelocortical multiple sclerosis) and brains that had cerebral white-matter discolorations or demyelinated lesions (referred to as typical multiple sclerosis). These individuals with myelocortical multiple sclerosis were matched by age, sex, MRI protocol, multiple sclerosis disease subtype, disease duration, and Expanded Disability Status Scale, with individuals with typical multiple sclerosis. Demyelinated lesion area in tissue sections of cerebral white matter, spinal cord, and cerebral cortex from individuals classed as having myelocortical and typical multiple sclerosis were compared using myelin protein immunocytochemistry. Neuronal densities in cortical layers III, V, and VI from five cortical regions not directly connected to spinal cord (cingulate gyrus and inferior frontal cortex, superior temporal cortex, and superior insular cortex and inferior insular cortex) were also compared between the two groups and with aged-matched post-mortem brains from individuals without evidence of neurological disease. Findings Brains and spinal cords were collected from 100 deceased patients between May, 1998, and November, 2012, and this retrospective study was done between Sept 6, 2011, and Feb 2, 2018. 12 individuals were identified as having myelocortical multiple sclerosis and were compared with 12 individuals identified as having typical multiple sclerosis. Demyelinated lesions were detected in spinal cord and cerebral cortex, but not in cerebral white matter, of people with myelocortical multiple sclerosis. Cortical demyelinated lesion area was similar between myelocortical and typical multiple sclerosis (median 4·45% [IQR 2·54-10·81] in myelocortical vs 9·74% [1·35-19·50] in typical multiple sclerosis; p=0·5512). Spinal cord demyelinated area was significantly greater in typical than in myelocortical multiple sclerosis (median 3·81% [IQR 1·72-7·42] in myelocortical vs 13·81% [6·51-29·01] in typical multiple sclerosis; p=0·0083). Despite the lack of cerebral white-matter demyelination in myelocortical multiple sclerosis, mean cortical neuronal densities were significantly decreased compared with control brains (349·8 neurons per mm 2 [SD 51·9] in myelocortical multiple sclerosis vs 419·0 [43·6] in controls in layer III [p=0·0104]; 355·6 [46·5] vs 454·2 [48·3] in layer V [p=0·0006]; 366·6 [50·9] vs 458·3 [48·4] in layer VI [p=0·0049]). By contrast, mean cortical neuronal densities were decreased in typical multiple sclerosis brains compared with those from controls in layer V (392·5 [59·0] vs 454·2 [48·3]; p=0·0182) but not layers III and VI. Interpretation We propose that myelocortical multiple sclerosis is a subtype of multiple sclerosis that is characterised by demyelination of spinal cord and cerebral cortex but not of cerebral white matter. Cortical neuronal loss is not accompanied by cerebral white-matter demyelination and can be an independent pathological event in myelocortical multiple sclerosis. Compared with control brains, cortical neuronal loss was greater in myelocortical multiple sclerosis cortex than in typical multiple sclerosis cortex. The molecular mechanisms of primary neuronal degeneration and axonal pathology in myelocortical multiple sclerosis should be investigated in future studies. Funding US National Institutes of Health and National Multiple Sclerosis Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(18)30245-x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Demyelination of cortical grey matter is an important characteristic of MS, and in many patients the proportion of demyelinated grey matter outweighs that of demyelinated white matter.

    “Demyelination of the cortical grey matter is an important characteristic of MS, and the proportion of demyelinated grey matter outweighs that of demyelinated white matter in many patients.46,47”

    From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [47]

    The Introduction describes cortical demyelination as a prominent feature of postmortem MS brains. The Discussion reports cortical demyelination without significant cerebral white-matter demyelination in the myelocortical MS subgroup (12 of 97 autopsy cases). It does not establish that the proportion of demyelinated grey matter exceeds that of white matter in many MS patients generally. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. [1]Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247– 69. 18558855
  2. [3]Bjartmar C, Kidd G, Mörk S, Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893– 901. 11117546
  3. [4]Filippi M, Rocca MA, Ciccarelli O, MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016; 15: 292– 303. 26822746 PMC4760851
  4. [5]van Munster CE, Uitdehaag BM. Outcome Measures in Clinical Trials for Multiple Sclerosis. CNSDrugs 2017; 31: 217– 36. PMC5336539 28185158
  5. [6]Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013; 12: 669– 76. 23743084
  6. [7]de Groot CJ, Bergers E, Kamphorst W, Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001; 124: 1635– 45. 11459754
  7. [8]Fisher E, Chang A, Fox RJ, Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007; 62: 219– 28. 17427920
  8. [9]Rudick RA, Fisher E, Lee JC, Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000; 6: 365– 72. 11212130
  9. [10]Fisher E, Rudick RA, Simon JH, Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412– 20. 12427893
  10. [11]Korteweg T, Rovaris M, Neacsu V, Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Mult Scler 2009; 15: 465– 71. 19091881
  11. [13]Wegner C, Esiri MM, Chance SA, Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67: 960– 7. 17000961
  12. [14]Klaver R, Popescu V, Voorn P, Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. JNeuropatholExp Neurol 2015; 74: 453– 8. 25853695
  13. [15]Magliozzi R, Howell OW, Reeves C, A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477– 93. 20976767
  14. [16]Tedeschi G, Lavorgna L, Russo P, Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280– 5. 16043800
  15. [17]Fisher E, Lee JC, Nakamura K, Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255– 65. 18661561
  16. [18]Fisniku LK, Chard DT, Jackson JS, Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247– 54. 18570297
  17. [19]Roosendaal SD, Bendfeldt K, Vrenken H, Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011; 17: 1098– 106. 21586487
  18. [20]Dalton CM, Chard DT, Davies GR, Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101– 7. 14998914
  19. [21]Chard DT, Griffin CM, Rashid W, Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 387– 91. 15327034
  20. [22]De Stefano N, Giorgio A, Battaglini M, Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868– 76. 20530323
  21. [23]De Stefano N, Matthews PM, Filippi M, Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157– 62. 12682324
  22. [24]Sailer M, Fischl B, Salat D, Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126: 1734– 44. 12805100
  23. [25]Shiee N, Bazin PL, Zackowski KM, Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One 2012; 7: e37049. 22615886 PMC3352847
  24. [26]Nakamura K, Fox R, Fisher E. CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage 2011; 54: 278– 89. 20674750 PMC2965022
  25. [27]Young EA, Fowler CD, Kidd GJ, Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008; 63: 428– 35. 18438950
  26. [28]Levesque I, Sled JG, Narayanan S, The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study. J Magn Reson Imaging 2005; 21: 103– 10. 15666408
  27. [29]van Leijsen EMC, van Uden IWM, Ghafoorian M, Nonlinear temporal dynamics of cerebral small vessel disease: The RUN DMC study. Neurology 2017; 89: 1569– 77. 28878046 PMC5634663

Cited by

Sorted by citations

Authors
Trapp, B. D., Vignos, M., Dudman, J., Chang, A., Fisher, E., Staugaitis, S. M., Battapady, H., Mork, S., Ontaneda, D., Jones, S. E., Fox, R. J., Chen, J., Nakamura, K., & Rudick, R. A.
Affiliations
Cleveland Clinic (US)
Corresponding author
Trapp, Bruce D
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2018-10
Volume
17
Issue
10
Pages
870-884
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2888417313
Cited by
146
References
2
Citations by year
2026: 6 · 2025: 12 · 2024: 15 · 2023: 14 · 2022: 21 · 2021: 29 · 2020: 22 · 2019: 21 · 2018: 6
FWCI
14.83
Type
journal article
Language
en
Open access
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (P50NS38667, R35NS09730)
  • Novartis
  • National Institute of Mental Health
  • Biogen
  • National Institute of Neurological Disorders and Stroke
  • National Center for Advancing Translational Sciences (CTSA KL2, KL2TR000440)
  • National Multiple Sclerosis Society (RG 4348-A-7)
  • Disarm Therapeutics
  • Merck
  • Genentech
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
Keywords
multiple sclerosis, demyelinating lesions, myelin proteins, cortical layers, postmortem brain, spinal cord demyelination, neurological deficit, myelopathy, cingulate gyrus
MeSH terms
Adult, Aged, Aged, 80 and over, Autopsy, Cerebral Cortex, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Neurons, Retrospective Studies, Spinal Cord, White Matter

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review